Other Events ·
On August 14, 2026, Pfizer and Valneva announced that the European Medicines Agency validated the Marketing…
VALNValneva SE
On August 14, 2026, Pfizer and Valneva announced that the European Medicines Agency validated the Marketing Authorization Application for PF-07307405, a 6-valent Lyme disease vaccine candidate. The application is based on Phase 3 VALOR trial results showing efficacy exceeding 70% in preventing Lyme disease among participants aged five and older. This validation marks a significant milestone as the EMA begins its assessment of the first potential human vaccine for Lyme disease in Europe. Valneva SE operates in the biopharmaceutical industry, specializing in the development, manufacturing, and commercialization of prophylactic vaccines.